FMR LLC reports 10.6% stake in Kiniksa Class A

FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock.

Rhea-AI Filing Summary

FMR LLC reports beneficial ownership in Kiniksa Pharmaceuticals International plc Class A common stock. The filing shows FMR LLC (and Abigail P. Johnson in related capacity) beneficially owns 4,854,354.23 shares, equal to 10.6% of the class as reported with a 02/27/2026 reference. The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. The schedule includes an Exhibit 99 13d-1(k)(1) agreement and signatures by an authorized representative on 03/05/2026.

Insights

Institutional Ownership Analyst

FMR LLC holds a sizable passive stake of 10.6% in Kiniksa.

FMR LLC is reported as beneficial owner of 4,854,354.23 Class A shares with sole dispositive power and nearly equivalent sole voting power, indicating control over disposition decisions. The filing is a Schedule 13G format, consistent with passive/beneficial ownership reporting.

Potential implications depend on holder behavior; subsequent filings could show changes. The excerpt references a 03/05/2026 signature and an Exhibit 99 13d-1(k)(1) agreement; further filings may clarify any voting arrangements or disposition plans.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in KNSA?

FMR LLC reports beneficial ownership of 4,854,354.23 Class A shares, equal to 10.6% of the class. The filing cites sole dispositive power and nearly equivalent sole voting power over those shares.

Does Abigail P. Johnson appear in the KNSA ownership filing?

Yes. Abigail P. Johnson is listed in the filing with beneficial ownership of 4,854,354.23 shares and a reported 10.6% stake, reflecting the same dispositive authority recorded for FMR LLC.

What form was filed to report this ownership for Kiniksa (KNSA)?

A Schedule 13G was filed to report the position in Class A common stock. The filing references an Exhibit 99 13d-1(k)(1) agreement and includes authorized signatures dated 03/05/2026.

What voting and disposition powers are shown in the KNSA filing?

The cover lists sole voting power of 4,852,623 shares and sole dispositive power of 4,854,354.23 shares. Shared voting and dispositive powers are reported as 0.00.

Does the filing indicate any other person holds >5% of KNSA on behalf of FMR?

The filing states that no other single person's interest exceeds 5% of the Class A common stock. A listing of underlying shareholders of registered investment companies is not required by the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 10:05 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

KINIKSA PHARMACEUTICALS INTERNATIONAL PL

(Name of Issuer)

CLASS A COMMON STOCK

(Title of Class of Securities)

02/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,852,623.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,854,354.23
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,854,354.23

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.6 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,854,354.23
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,854,354.23

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KINIKSA PHARMACEUTICALS INTERNATIONAL PL
(b)	Address of issuer's principal executive offices: 105 PICCADILLY,SECOND FLOOR,LONDON,X0,W1J 7NJ
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: CLASS A COMMON STOCK
(e)	CUSIP No.: G52694109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4854354.23
(b)	Percent of class: 10.6 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 4854354.23
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of KINIKSA PHARMACEUTICALS INTERNATIONAL PL. No one other person's interest in the CLASS A COMMON STOCK of KINIKSA PHARMACEUTICALS INTERNATIONAL PL is more than five percent of the total outstanding CLASS A COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	03/05/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	03/05/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.